The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
Open accessAbstract
BACKGROUND: Immune checkpoint inhibitors and targeted therapies have dramatically improved outcomes in patients with advanced melanoma, but approximately half these patients will not have a durable benefit. Phase 1-2 trials of adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) have shown promising responses, but data from phase 3 trials are lacking to determine the role of TILs in treating advanced melanoma. METHODS: TILs was preceded by nonmyeloablative, lymphodepleting chemotherapy (cyclophosphamide plus fludarabine) and followed by high-dose interleukin-2. The primary end point was progression-free survival. RESULTS: A total of 168 patients (86% with disease refractory to anti-programmed death 1 treatment) were assigned to receive TILs (84 patients) or ipilimumab (84 patients). In the intention-to-treat population, median progression-free survival was 7.2 months (95% confidence interval [CI], 4.2 to 13.1) in the TIL group and 3.1 months (95% CI, 3.0 to 4.3) in the ipilimumab group (hazard ratio for progression or death, 0.50; 95% CI, 0.35 to 0.72; P<0.001); 49% (95% CI, 38 to 60) and 21% (95% CI, 13 to 32) of the patients, respectively, had an objective response. Median overall survival was 25.8 months (95% CI, 18.2 to not reached) in the TIL group and 18.9 months (95% CI, 13.8 to 32.6) in the ipilimumab group. Treatment-related adverse events of grade 3 or higher occurred in all patients who received TILs and in 57% of those who received ipilimumab; in the TIL group, these events were mainly chemotherapy-related myelosuppression. CONCLUSIONS: In patients with advanced melanoma, progression-free survival was significantly longer among those who received TIL therapy than among those who received ipilimumab. (Funded by the Dutch Cancer Society and others; ClinicalTrials.gov number, NCT02278887.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Longitudinal data analysis using generalized linear models
LIANG, K.-Y., & ZEGER, S. L. (1986) · Biometrika · doi:10.1093/biomet/73.1.13 · Cited by 18,550
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationFive-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910836 · Cited by 3,723
Self-citationWolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,140
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
Tawbi, H. A., Schadendorf, D., Lipson, E. J., Ascierto, P. A., Matamala, L., Castillo Gutiérrez, E., Rutkowski, P., Gogas, H. J., Lao, C. D., De Menezes, J. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2109970 · Cited by 1,883
A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating Lymphocytes
Rosenberg, S. A., Spiess, P., & Lafreniere, R. (1986) · Science · doi:10.1126/science.3489291 · Cited by 1,880
Generalized Estimating Equations
Hardin, J. W., & Hilbe, J. M. (2002) · doi:10.1201/9781420035285 · Cited by 1,766
Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma
Robert, C., Grob, J. J., Stroyakovskiy, D., Karaszewska, B., Hauschild, A., Levchenko, E., Chiarion Sileni, V., Schachter, J., Garbe, C., Bondarenko, I., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1904059 · Cited by 1,389
Self-citationDudley, M. E., Yang, J. C., Sherry, R., Hughes, M. S., Royal, R., Kammula, U., Robbins, P. F., Huang, J., Citrin, D. E., Leitman, S. F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5449 · Cited by 1,332
Robert, C., Ribas, A., Schachter, J., Arance, A., Grob, J.-J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C. M., Lotem, M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30388-2 · Cited by 1,159
Self-citationMalek, T. R. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090357 · Cited by 1,079
Dummer, R., Ascierto, P. A., Gogas, H. J., Arance, A., Mandala, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsova, I., Gutzmer, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30142-6 · Cited by 1,037
Self-citationRosenberg, S. A., Yannelli, J. R., Yang, J. C., Topalian, S. L., Schwartzentruber, D. J., Weber, J. S., Parkinson, D. R., Seipp, C. A., Einhorn, J. H., & White, D. E. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.15.1159 · Cited by 1,019
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W. J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R., Weber, J. S., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz011 · Cited by 945
Groenvold, M., Petersen, M. A., Aaronson, N. K., Arraras, J. I., Blazeby, J. M., Bottomley, A., Fayers, P. M., de Graeff, A., Hammerlid, E., Kaasa, S., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.06.022 · Cited by 678
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Michielin, O., van Akkooi, A. C. J., Ascierto, P. A., Dummer, R., & Keilholz, U. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz411 · Cited by 617
Self-citationBesser, M. J., Shapira-Frommer, R., Treves, A. J., Zippel, D., Itzhaki, O., Hershkovitz, L., Levy, D., Kubi, A., Hovav, E., Chermoshniuk, N., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0041 · Cited by 462
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma
Sarnaik, A. A., Hamid, O., Khushalani, N. I., Lewis, K. D., Medina, T., Kluger, H. M., Thomas, S. S., Domingo-Musibay, E., Pavlick, A. C., Whitman, E. D., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00612 · Cited by 451
Adoptive cellular therapy: A race to the finish line
June, C. H., Riddell, S. R., & Schumacher, T. N. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa3643 · Cited by 403
Self-citationDudley, M. E., Wunderlich, J. R., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R. M., Marincola, F. M., Leitman, S. F., Seipp, C. A., et al. (2002) · Journal of Immunotherapy · doi:10.1097/00002371-200205000-00007 · Cited by 357
Andersen, R., Donia, M., Ellebaek, E., Borch, T. H., Kongsted, P., Iversen, T. Z., Hölmich, L. R., Hendel, H. W., Met, Ö., Andersen, M. H., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1879 · Cited by 317
Self-citationTran, K. Q., Zhou, J., Durflinger, K. H., Langhan, M. M., Shelton, T. E., Wunderlich, J. R., Robbins, P. F., Rosenberg, S. A., & Dudley, M. E. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31818403d5 · Cited by 287
Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Di Giacomo, A. M., Mortier, L., Rutkowski, P., Hassel, J. C., McNeil, C. M., Kalinka, E. A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00995 · Cited by 247
Ascierto, P. A., Melero, I., Bhatia, S., Bono, P., Sanborn, R. E., Lipson, E. J., Callahan, M. K., Gajewski, T., Gomez-Roca, C. A., Hodi, F. S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.9520 · Cited by 238
Ackerman, A., Klein, O., McDermott, D. F., Wang, W., Ibrahim, N., Lawrence, D. P., Gunturi, A., Flaherty, K. T., Hodi, F. S., Kefford, R., et al. (2014) · Cancer · doi:10.1002/cncr.28620 · Cited by 223
Pires da Silva, I., Ahmed, T., Reijers, I. L. M., Weppler, A. M., Betof Warner, A., Patrinely, J. R., Serra-Bellver, P., Allayous, C., Mangana, J., Nguyen, K., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00097-8 · Cited by 221
Self-citationPilon-Thomas, S., Kuhn, L., Ellwanger, S., Janssen, W., Royster, E., Marzban, S., Kudchadkar, R., Zager, J., Gibney, G., Sondak, V. K., et al. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31826e8f5f · Cited by 198
van den Berg, J. H., Heemskerk, B., van Rooij, N., Gomez-Eerland, R., Michels, S., van Zon, M., de Boer, R., Bakker, N. A. M., Jorritsma-Smit, A., van Buuren, M. M., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000848 · Cited by 194
Self-citationZimmer, L., Apuri, S., Eroglu, Z., Kottschade, L. A., Forschner, A., Gutzmer, R., Schlaak, M., Heinzerling, L., Krackhardt, A. M., Loquai, C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.009 · Cited by 190
Ellebaek, E., Iversen, T. Z., Junker, N., Donia, M., Engell-Noerregaard, L., Met, Ö., Hölmich, L. R., Andersen, R. S., Hadrup, S. R., Andersen, M. H., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-169 · Cited by 172
Self-citationHodi, F. S., Chiarion‐Sileni, V., Lewis, K. D., Grob, J., Rutkowski, P. L., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.9522 · Cited by 84
Self-citationFriedman, C. F., Spencer, C. N., Cabanski, C. R., Panageas, K. S., Wells, D. K., Ribas, A., Tawbi, H. A., Tsai, K. K., Postow, M. A., Shoushtari, A. N., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003853 · Cited by 48
Vanderwalde, A. M., Moon, J., Kendra, K. L., Khushalani, N. I., Collichio, F. A., Sosman, J. A., Ikeguchi, A. P., Victor, A. I., Truong, T., Chmielowski, B., et al. (2022) · Cancer Research · doi:10.1158/1538-7445.am2022-ct013 · Cited by 15
Cited by
Exploring treatment options in cancer: tumor treatment strategies
Liu, B., Zhou, H., Tan, L., Siu, K. T. H., & Guan, X.-Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01856-7 · Cited by 1,201
The cancer-immunity cycle: Indication, genotype, and immunotype
Mellman, I., Chen, D. S., Powles, T., & Turley, S. J. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.011 · Cited by 953
Long, G. V., Swetter, S. M., Menzies, A. M., Gershenwald, J. E., & Scolyer, R. A. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00821-8 · Cited by 746
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
Albelda, S. M. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00832-4 · Cited by 517
Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment
Polak, R., Zhang, E. T., & Kuo, C. J. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00706-6 · Cited by 298
Metadata
- Authors
- Rohaan, M. W., Borch, T. H., van den Berg, J. H., Met, Ö., Kessels, R., Geukes Foppen, M. H., Stoltenborg Granhøj, J., Nuijen, B., Nijenhuis, C., Jedema, I., van Zon, M., Scheij, S., Beijnen, J. H., Hansen, M., Voermans, C., Noringriis, I. M., Monberg, T. J., Holmstroem, R. B., Wever, L. D. V., van Dijk, M., Grijpink-Ongering, L. G., Valkenet, L. H. M., Torres Acosta, A., Karger, M., Borgers, J. S. W., ten Ham, R. M. T., Retèl, V. P., van Harten, W. H., Lalezari, F., van Tinteren, H., van der Veldt, A. A. M., Hospers, G. A. P., Stevense-den Boer, M. A. M., Suijkerbuijk, K. P. M., Aarts, M. J. B., Piersma, D., van den Eertwegh, A. J. M., de Groot, J.-W. B., Vreugdenhil, G., Kapiteijn, E., Boers-Sonderen, M. J., Fiets, W. E., van den Berkmortel, F. W. P. J., Ellebaek, E., Hölmich, L. R., van Akkooi, A. C. J., van Houdt, W. J., Wouters, M. W. J. M., van Thienen, J. V., Blank, C. U., Meerveld-Eggink, A., Klobuch, S., Wilgenhof, S., Schumacher, T. N., Donia, M., Svane, I. M., & Haanen, J. B. A. G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-12-08
- Volume
- 387
- Issue
- 23
- Pages
- 2113-2125
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4311584464
- Cited by
- 568
- References
- 35
- FWCI
- 39.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.